Sees FY26 Adjusted EBITDA of $760M-$790M, or 23.1%-27.9% growth. The Amedysis and LHC acquisition is expected to contribute approximately $30M in adjusted EBITDA in 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health reports Q4 adjusted EPS 33c, consensus 35c
- BrightSpring Health Services, Inc. (BTSG) Q4 Earnings Cheat Sheet
- BrightSpring Health price target raised to $55 from $50 at BTIG
- BrightSpring Health price target raised to $46 from $42 at TD Cowen
- BrightSpring Health price target raised to $46 from $40 at BMO Capital